Arvinas

Arvinas, based in New Haven and listed as ARVN, is the PROTAC pioneer whose vepdegestrant became the first approved targeted protein degrader in 2026. Founded on Craig Crews' PROTAC technology, it developed vepdegestrant, an oestrogen receptor degrader, with Pfizer; the FDA approved it as Veppanu on 1 May 2026 for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after endocrine therapy. Arvinas and Pfizer then licensed exclusive global rights to Rigel Pharmaceuticals, which took over the US launch; the licence took effect in June 2026 with a 70 million dollar upfront payment shared between Arvinas and Pfizer, and up to 320 million dollars in further milestones plus royalties. Its pipeline includes ARV-393 against BCL6 and ARV-102 against LRRK2 in neurology. OnCo links it to HR-positive, HER2-negative breast cancer, to PROTACs and molecular glues, to the bottleneck of undruggable drivers, and to ideas for an open degrader consortium and for destroying the truncated androgen receptor. Whether degraders can reach transcription factors that inhibitors never could is the open question the first approval makes urgent. Vepdegestrant has its own page.